ClinicalTrials.gg
RecruitingNCT07267949END-AF-1Updated Sep 30, 2026

Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation

A Phase 2 interventional study of AP31969 and Placebo in Atrial Fibrillation (AF), sponsored by Acesion Pharma. Recruiting at 46 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Acesion Pharma · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Sep 30, 2026Site recruiting status changedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 255 studies in Atrial Fibrillation with a site in Netherlands — 33 open to participants now, 49 under way, 2 of them phase 3. Atrial Fibrillation · Netherlands.

Planned enrollment
110th of 192
200 · median 250
Started
2025
with 11 others
Phase 2
20 of 255
3 open now
Primary completion
2027-05
later than 21 of 48 live
Registered
249th of 255
by date

Among the 255 studies in Atrial Fibrillation with a site in Netherlands, this one is the 110th largest by planned enrollment of the 192 interventional ones that give a count, is one of 12 that started in 2025, is one of 20 in phase 2, reaches primary completion later than 21 of the 48 other live ones, and was the 249th registered.

Atrial Fibrillation

4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

33 of the 255 studies in Atrial Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 255 studies in Atrial Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.

Read the detailed description

The key goal of this clinical trial is to assess the effectiveness of different doses of AP31969 in lowering Atrial Fibrillation (AF) burden and its safety.

Participants will be randomly assigned to one of the following groups:

  • AP31969 at 100 mg, 200 mg, or 350 mg doses
  • AP31969 500 mg (not included at the trial start)
  • Placebo (inactive treatment and has no active properties). The placebo group serves as the comparator for AP31969. All treatments are given orally, twice daily.

The trial includes 3 periods: screening (up to 4 weeks), treatment (12 weeks), and follow-up (30 days). The duration of the trial for a participant is approximately 20 weeks.

Participants will receive an implantable loop recorder and undergo assessments during the visits at specific times, for example blood and urine analyses, and electrocardiogram.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

Keywords

  • Atrial Fibrillation
  • AP31969
  • SK channel inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written .
  • Age 18 or older.
  • documented diagnosis of paroxysmal or persistent AF.
  • AF history at screening indicating an expected AF burden of 1-90%, i.e., at least 1 self-terminating AF episode within 4 months prior to the screening visit.
  • AF burden of ≥ 1% and ≤ 90% assessed with an ECG patch device during the screening period prior to the randomisation visit.
  • Investigator and participant agreement to avoid non-trial related rhythm control intervention for the duration of the trial, including:

    • Antiarrhythmic drug class I and/or III (including amiodarone)
    • Electrical or pharmacological cardioversion
    • AF ablation procedure
  • Willing to have a loop recorder implanted.

Exclusion criteria

Exclusion Criteria:

  • Prior AF ablation procedure other than pulmonary vein isolation (PVI) only.
  • Any of the following events within 4 weeks prior to the screening visit: Myocardial infarction, Unstable angina pectoris, Stroke or transient, ischaemic attack, Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG), Peripheral revascularisation procedure.
  • Cardiac pacing device e.g. pacemaker and cardiac resynchronization therapy device with atrial or ventricular pacing for > 5% of the time or existing implantable loop recorder.
  • Heart failure, class III (3) or IV (4).
  • \< 40% based on imaging (e.g. echocardiography) performed within 6 months prior to or during the screening visit.
  • valvular heart disease, including severe aortic stenosis, severe mitral regurgitation and/or severe mitral stenosis, in the opinion of the investigator.
  • (Fridericia, QTcF) interval > 450 ms for males and > 470 ms for females at screening.
  • \<60 mL/min /1.73 m² based on creatine and CKD-EPI formula
  • Use of antiarrhythmic drug class I and/or III within 7 days or, for amiodarone, within 3 months prior to the screening visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AP31969 100 mg

    Tablets, Twice daily, 12 Weeks

    Drug: AP31969

  • Experimental
    AP31969 200 mg

    Tablets, Twice daily, 12 Weeks

    Drug: AP31969

  • Experimental
    AP31969 350 mg

    Tablets, Twice daily, 12 Weeks

    Drug: AP31969

  • Experimental
    AP31969 500 mg

    Tablets, Twice daily, 12 Weeks

    Drug: AP31969

  • Placebo comparator
    Placebo

    Tablets, Twice daily, 12 Weeks

    Drug: Placebo

Interventions

  • Tablets, Oral, Twice daily.

  • DrugPlacebo

    Tablets, oral, Twice daily.

06

What researchers measure

Primary outcomes

  1. Atrial fibrillation burden

    Measured through implantable loop recorder. Calculated as the amount of time with AF relative to the amount of time the participant is under observation (expressed as a %).

    Time frame: From week 2 to week 12

Secondary outcomes

  1. Number of atrial fibrillation episodes

    Measured through implantable loop recorder.

    Time frame: From week 2 to week 12

  2. Change from baseline in Atrial Fibrillation Effect on Quality-of-Life

    Patient reported outcome. Reporting on a scale of 1 to 7, where 7 is the worse outcome.

    Time frame: Week 12

  3. Number of ventricular tachycardia episodes > 30 seconds of duration

    Measured through implantable loop recorder.

    Time frame: From week 0 to week 12

07

Study locations

38 of 46 sites recruiting
  • UMHAT "Sveti Georgi" EAD, Department of Invasive Cardiology
    Plovdiv, PD 4002, Bulgaria
    Recruiting
  • Acibadem City Clinic, Cardiology Department
    Sofia, SOF 1000, Bulgaria
    Recruiting
  • MHAT National Cardiology Hospital EAD, Cardiology Department
    Sofia, SOF 1365, Bulgaria
    Withdrawn

    Not enrolling at this site — choose another above.

  • Aleksandrovska University Hospital, Clinic of Cardiology
    Sofia, SOF 1431, Bulgaria
    Recruiting
  • SHATC Cardiolife, Invasive Cardiology
    Varna, VAR 9000, Bulgaria
    Recruiting
  • Medical Center Nova Clinic
    Varna, VAR 9020, Bulgaria
    Recruiting
  • University Hospital Herlev and Gentofte Department of Cardiology
    Hellerup, 2730, Denmark
    Recruiting
  • Viborg Hospital, Department of Cardiology
    Viborg, 8800, Denmark
    Recruiting
  • Sana Kliniken Oberfranken, Klinikum Coburg Kardiologie und Innere Medizin
    Coburg, 96450, Germany
    Recruiting
  • Universitätsklinikum Frankfurt Medizinische Klinik III - Kardiologie, Angiologie, Hämostaseologie, Nephrologie
    Frankfurt, 60590, Germany
    Recruiting
  • Universitaets Klinikum Hamburg-Eppendorf (UKE Hamburg), Kardiologie
    Hamburg, 20246, Germany
    Recruiting
  • Pécsi Tudományegyetem Szivgyógyászati Klinika (Cardiology Clinic, University of Pecs)
    Pécs, Hungary 7622, Hungary
    Not yet recruiting
  • Budai Irgalmasrendi Kórház
    Budapest, 1023, Hungary
    Recruiting
  • Semmelweis Egyetem Városmajori Sziv- és Érsebészeti Klinika
    Budapest, 1122, Hungary
    Recruiting
  • Soproni Gyógyközpont Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet
    Sopron, 9400, Hungary
    Withdrawn

    Not enrolling at this site — choose another above.

  • Szent-Györgyi Albert Klinikai Központ, Belgyógyászati Klinika
    Szeged, 6725, Hungary
    Recruiting
  • Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház-Rendelőintézet
    Szolnok, 5000, Hungary
    Recruiting
  • Belvárosi Egészségház, Platán Magánklinika
    Zalaegerszeg, 8900, Hungary
    Recruiting
  • Policlinico Sant'Orsola Cardiology Department
    Bologna, BO 40138, Italy
    Recruiting
  • Arcispedale Sant'Anna, Cardiology Department
    Cona, FE 444124, Italy
    Recruiting
  • Dell'Angelo Hospital, Cardiology Department
    Mestre, VE 30174, Italy
    Recruiting
  • ASST Grande Ospedale Metropolitano Niguarda Cardiology 3 - Electrophysiology "De Gasperis" Cardio Center
    Milan, 20162, Italy
    Recruiting
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Cardio - Thoracic- Vascular Diseases,
    Milan, 20122, Italy
    Not yet recruiting
  • University of Modena and Reggio Emilia, Policlinico di Modena, Cardiology Department
    Modena, 30174, Italy
    Recruiting
  • Rijnstate Ziekenhuis, Cardiology Department
    Arnhem, 6815 AD, Netherlands
    Recruiting
  • Deventer Ziekenhuis, Cardiology Department
    Deventer, 7416 SE, Netherlands
    Recruiting
  • Martini Hospital Groningen, Cardiology Department
    Groningen, 9728 NT, Netherlands
    Recruiting
  • Spaarne Gasthuis, Cardiology Department
    Haarlem, 2035 RC, Netherlands
    Recruiting
  • Frisius MC Leeuwarden, Hart- en Vaatcentrum
    Leeuwarden, 8934 AD, Netherlands
    Withdrawn

    Not enrolling at this site — choose another above.

  • Maastricht University Medical Center, Cardiology Department
    Maastricht, 6229 HX, Netherlands
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • HagaZiekenhuis, Cardiology/Electrophysiology Unit
    The Hague, 2545 AA, Netherlands
    Recruiting
  • Rivierenland Hospital, Cardiology Department
    Tiel, 4002 WP, Netherlands
    Recruiting
  • Máxima Medisch Centrum, Cardiology Department
    Veldhoven, 5504 DB, Netherlands
    Recruiting
  • Centrum Medyczne KERmed Cardiology Department
    Bydgoszcz, 85-231, Poland
    Recruiting
  • Małopolskie Centrum Sercowo-Naczyniowe PAKS Oddział Intensywnej Opieki Kardiologicznej
    Chrzanów, 85-231, Poland
    Recruiting
  • Polsko-Amerykańskie Kliniki Serca III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
    Dąbrowa Górnicza, 41-300, Poland
    Recruiting
  • Gornoslaskie Centrum Medyczne im. prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego w Katowicach
    Katowice, 40-635, Poland
    Not yet recruiting
  • Upper-Silesian Medical Center 2nd Department of Cardiology
    Katowice, 40-635, Poland
    Not yet recruiting
  • One Day Med Sp. z o.o. Clinical Trials Department
    Szczecin, 70-419, Poland
    Recruiting
  • Polsko-Amerykańskie Kliniki Serca X Oddział Kardiologii Inwazyjnej, Elektrofizjologii i Elektrostymulacji w Tychach im
    Tychy, 43-100, Poland
    Recruiting
  • Institute for Cardiovascular Disease "Dedinje" Department for Electrophysiology
    Belgrade, Serbia
    Recruiting
  • University Clinical Centre of Serbia Department for Intensive Care in Arrhythmology
    Belgrade, Serbia
    Recruiting
  • Institute for Cardiovascular Diseases Vojvodina Department of Interventional Electrophysiology
    Kamenitz, Serbia
    Recruiting
  • University Clinical Center Kragujevac Clinic of Cardiology (Depar. Electrophysiology)
    Kragujevac, Serbia
    Recruiting
  • University Clinical Center Nis Clinic for Cardiovascular Diseases Bulevar
    Niš, Serbia
    Recruiting
  • Health Center Uzice Cardiology Department
    Užice, 33100, Serbia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified external researchers may request access to anonymized data and needed trial documentation. Requests are evaluated on the basis of scientific merit. Any use of and access to the data must respect the privacy of the participants and will only be provided if applicable laws and regulations allow this.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for May 2027, 19 months after the start.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 19 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2026 → May 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2025
First posted
Dec 5, 2025
StartActual
Oct 22, 2025
Primary completionEst.
May 2027was Nov 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 6 sites changed recruiting status (3 now recruiting, 2 now withdrawn, …)
Show 6 sites
  • Soproni Gyógyközpont Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet · Sopron, HungaryNot yet recruiting→Withdrawn
  • Frisius MC Leeuwarden, Hart- en Vaatcentrum · Leeuwarden, NetherlandsRecruiting→Withdrawn
  • Maastricht University Medical Center, Cardiology Department · Maastricht, NetherlandsNot yet recruiting→Active, not recruiting
  • HagaZiekenhuis, Cardiology/Electrophysiology Unit · The Hague, NetherlandsNot yet recruiting→Recruiting
  • Institute for Cardiovascular Disease "Dedinje" Department for Electrophysiology · Belgrade, SerbiaNot yet recruiting→Recruiting
  • Health Center Uzice Cardiology Department · Užice, SerbiaNot yet recruiting→Recruiting
Show 2 added (1 Hungary, 1 Italy)
  • Pécsi Tudományegyetem Szivgyógyászati Klinika (Cardiology Clinic, University of Pecs) · Pécs, Hungary
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Cardio - Thoracic- Vascular Diseases, · Milan, Italy
Sep 30, 2026
Primary completion
Nov 2026→May 2027
Sep 30, 2026
Study completion
Dec 2026→Jun 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    2 sites added. 6 sites changed recruiting status (3 now recruiting, 2 now withdrawn, …)
    Show 6 sites
    • Soproni Gyógyközpont Soproni Erzsébet Oktató Kórház és Rehabilitációs Intézet · Sopron, HungaryNot yet recruiting→Withdrawn
    • Frisius MC Leeuwarden, Hart- en Vaatcentrum · Leeuwarden, NetherlandsRecruiting→Withdrawn
    • Maastricht University Medical Center, Cardiology Department · Maastricht, NetherlandsNot yet recruiting→Active, not recruiting
    • HagaZiekenhuis, Cardiology/Electrophysiology Unit · The Hague, NetherlandsNot yet recruiting→Recruiting
    • Institute for Cardiovascular Disease "Dedinje" Department for Electrophysiology · Belgrade, SerbiaNot yet recruiting→Recruiting
    • Health Center Uzice Cardiology Department · Užice, SerbiaNot yet recruiting→Recruiting
    Show 2 added (1 Hungary, 1 Italy)
    • Pécsi Tudományegyetem Szivgyógyászati Klinika (Cardiology Clinic, University of Pecs) · Pécs, Hungary
    • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Department of Cardio - Thoracic- Vascular Diseases, · Milan, Italy
    Primary completion Nov 2026→May 2027
    Study completion Dec 2026→Jun 2027
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07267949
Lead sponsor
Acesion Pharma
Responsible party
Sponsor
First posted
Dec 5, 2025
Start date
Oct 22, 2025
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Birgitte Vestbjerg
Contact
bve@acesionpharma.com
+0045 2077 2575

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AP31969

Start the discussion